Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the company. The Danish pharmaceutical giant announced Friday that ...

Ozempic users find that it not only promotes weight loss but also helps lower the risk of heart disease, high blood pressure, type 2 diabetes, and other obesity-related conditions.

May 16 (Reuters) - Ozempic-maker Novo Nordisk (NOVOb.CO), opens new tab on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the ...

Even doctors are baffled by her inability to regain weight, months after she stopped using Ozempic. “They can’t figure it out,” she said. “But I think it’s just because I’m getting ...

Lars Fruergaard Jørgensen said he was “surprised” that the Ozempic-maker’s largest shareholder, the Novo Nordisk Foundation, had decided to remove him. “I did not see this coming,” he ...

Copenhagen (AFP) – Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake ...

(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to ...

Danish drugmaker Novo Nordisk announced Friday that CEO Lars Fruergaard Jørgensen will step down, marking a significant leadership shakeup as the company navigates increasing pressure in the ...

The company behind popular new drug Ozempic says its CEO, Lars Fruergaard Jorgensen, will step down following a plunge in the company's share price. Danish pharmaceutical giant Novo Nordisk's ...

The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in the multi-billion pound fat jab market. Lars Fruergaard Jorgensen is ...